Safety Evaluation of Engineered Nanomaterials for Health Risk Assessment: An Experimental Tiered Testing Approach Using Pristine and Functionalized Carbon Nanotubes
Figure 7
(a–d) IL-6 and (e, f) TGF-β1 immunostaining patterns in controls (a, b) and differently treated rats: (c, d) MW-NH2 or (e, f) MW-COOH. (a) IL-6 and (b) TGF-β1 low labelling detected in control rats at all lung districts (e.g., bronchiolar, stromal, and alveolar levels). (c, e) Strongly IL-6-immunoreactive bronchiolar areas and collapsed alveoli, showing several markedly immunopositive cells (arrows), together with the presence of widespread black particulate. (d, f) Strong TGF-β1 immunoreactivity at stromal level (arrows) of some collapsed alveolar zones, with evident immunopositive cells (arrows). Objective magnification: 40x.
